ANN ARBOR, Mich.--(BUSINESS WIRE)--Jun. 18, 2019--
Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage
biopharmaceutical company developing novel treatments for orphan
endocrine diseases, today announced that Pharis Mohideen, M.D., is
departing the company to pursue a career opportunity closer to his home
in New Jersey, allowing him to spend more time with his family.
“I am proud to have been Millendo’s Chief Medical Officer, and to have
been part of the growth and success of the company for the past five
years,” said Dr. Mohideen, “I leave behind an exceptional team, with a
promising pipeline and a significant opportunity to have an impact in
rare endocrine diseases. I look forward to following Millendo’s success
in the years ahead.”
Julia C. Owens, Ph.D., President and CEO of Millendo commented, “Pharis
has played a critical role in the advancement of our clinical-stage
programs and supported the transformation of Millendo to a publicly
traded biopharmaceutical company. I would like to thank him for his
immense impact on the company and wish him success in the next chapter
of his career.”
The company has initiated a search for a new CMO and is working with Dr.
Mohideen on the details of his departure and transition plans for the
organization. Ryan Zeidan, Ph.D., Senior Vice President of Development,
will continue to lead the development activities at the company and in
the interim will also oversee the medical function.
About Millendo Therapeutics, Inc.
Millendo Therapeutics is a
late-stage biopharmaceutical company focused on developing novel
treatments for orphan endocrine diseases where current therapies do not
exist or are insufficient. As a leading orphan endocrine company,
Millendo creates distinct and transformative treatments where there is a
significant unmet medical need. The company is currently advancing
livoletide for the treatment of Prader-Willi syndrome and nevanimibe for
the treatment of classic congenital adrenal hyperplasia and endogenous
Cushing’s syndrome. For more information, please visit www.millendo.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190618005191/en/
Source: Millendo Therapeutics, Inc.
Millendo Investor Contact: